27914987|t|Tetrabromobisphenol A activates the hepatic interferon pathway in rats
27914987|a|Tetrabromobisphenol A (TBBPA) is a widely used flame retardant in printed circuit boards, paper, and textiles. In a two-year study, TBBPA showed evidence of uterine tumors in female Wistar-Han rats and liver and colon tumors in B6C3F1 mice. In order to gain further insight into early gene and pathway changes leading to cancer, we exposed female Wistar Han rats to TBBPA at 0, 25, 250, or 1000mg/kg (oral gavage in corn oil, 5Ã—/ week) for 13 weeks. Because at the end of the TBBPA exposure period, there were no treatment-related effects on body weights, liver or uterus lesions, and liver and uterine organ weights were within 10% of controls, only the high dose animals were analyzed. Analysis of the hepatic and uterine transcriptomes showed TBBPA -induced changes primarily in the liver (1000mg/kg), with 159 transcripts corresponding to 132 genes differentially expressed compared to controls (FDR=0.05). Pathway analysis showed activation of interferon (IFN) and metabolic networks. TBBPA induced few molecular changes in the uterus. Activation of the interferon pathway in the liver occurred after 13-weeks of TBBPA exposure, and with longer term TBBPA exposure this may lead to immunomodulatory changes that contribute to carcinogenic processes.
27914987	0	21	Tetrabromobisphenol A	T109	C0076220
27914987	22	31	activates	T052	C1879547
27914987	36	43	hepatic	T023	C0023884
27914987	44	62	interferon pathway	T044	C1512834
27914987	66	70	rats	T015	C0034721
27914987	71	92	Tetrabromobisphenol A	T109	C0076220
27914987	94	99	TBBPA	T109	C0076220
27914987	118	133	flame retardant	T120	C0016198
27914987	137	159	printed circuit boards	T073	C1707396
27914987	161	166	paper	T073	C0030351
27914987	172	180	textiles	T073	C0039717
27914987	187	195	two-year	T079	C0439234
27914987	196	201	study	T062	C2603343
27914987	203	208	TBBPA	T109	C0076220
27914987	228	242	uterine tumors	T191	C0042138
27914987	246	252	female	T032	C0086287
27914987	253	268	Wistar-Han rats	T015	C2700261
27914987	273	278	liver	T191	C0023903
27914987	283	295	colon tumors	T191	C0009375
27914987	299	310	B6C3F1 mice	T015	C2698297
27914987	356	360	gene	T028	C0017337
27914987	365	372	pathway	T044	C1704259
27914987	392	398	cancer	T191	C0027651
27914987	411	417	female	T032	C0086287
27914987	418	433	Wistar Han rats	T015	C2700261
27914987	437	442	TBBPA	T109	C0076220
27914987	472	483	oral gavage	T169	C2698653
27914987	487	495	corn oil	T109,T168	C0010029
27914987	501	505	week	T079	C0439230
27914987	514	519	weeks	T079	C0439230
27914987	547	552	TBBPA	T109	C0076220
27914987	553	561	exposure	T080	C0332157
27914987	613	625	body weights	T032	C0005910
27914987	627	632	liver	T033	C0577053
27914987	636	650	uterus lesions	T033	C0567079
27914987	656	661	liver	T023	C0736253
27914987	666	679	uterine organ	T023	C0736936
27914987	680	687	weights	T081	C0043100
27914987	707	715	controls	T096	C0009932
27914987	731	735	dose	T081	C0178602
27914987	736	743	animals	T008	C0003062
27914987	749	757	analyzed	T062	C0936012
27914987	759	767	Analysis	T062	C0936012
27914987	775	782	hepatic	T023	C0023884
27914987	787	794	uterine	T023	C0042149
27914987	795	809	transcriptomes	T086	C3178810
27914987	817	822	TBBPA	T109	C0076220
27914987	857	862	liver	T023	C0023884
27914987	885	896	transcripts	T114	C1519595
27914987	918	923	genes	T028	C0017337
27914987	939	948	expressed	T045	C0017262
27914987	961	969	controls	T096	C0009932
27914987	982	998	Pathway analysis	T170	C0868995
27914987	1006	1016	activation	T052	C1879547
27914987	1020	1030	interferon	T116,T121,T129	C0021747
27914987	1032	1035	IFN	T116,T121,T129	C0021747
27914987	1041	1059	metabolic networks	T044	C1706062
27914987	1061	1066	TBBPA	T109	C0076220
27914987	1104	1110	uterus	T023	C0042149
27914987	1112	1122	Activation	T052	C1879547
27914987	1130	1148	interferon pathway	T044	C1512834
27914987	1156	1161	liver	T023	C0023884
27914987	1177	1185	13-weeks	T079	C0439230
27914987	1189	1194	TBBPA	T109	C0076220
27914987	1195	1203	exposure	T080	C0332157
27914987	1226	1231	TBBPA	T109	C0076220
27914987	1232	1240	exposure	T080	C0332157
27914987	1258	1274	immunomodulatory	T061	C1963758
27914987	1275	1282	changes	T169	C0392747
27914987	1302	1324	carcinogenic processes	T191	C0596263